[
  {
    "date": "2025-11-24",
    "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/24/2025-20773/agency-information-collection-activities-proposed-collection-comment-request-human-drug-compounding",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits c",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-24",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; ALTIUS DIRECT ELECTRICAL NERVE STIMULATION SYSTEM",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/24/2025-20668/determination-of-regulatory-review-period-for-purposes-of-patent-extension-altius-direct-electrical",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALTIUS Direct Electrical Nerve Stimulation System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-24",
    "title": "Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/24/2025-20654/reauthorization-of-the-biosimilar-user-fee-act-public-meeting-request-for-comments",
    "abstract": "The Food and Drug Administration (FDA, the Agency, or we) is hosting a hybrid public meeting to discuss proposed recommendations for the reauthorization of the Biosimilar User Fee Act (BsUFA) for fiscal years (FYs) 2028 through 2032. The BsUFA authorizes FDA to collect user fees to support the process for the review of biosimilar biological products. The current legislative authority for BsUFA expires in September 2027. At that time, new legislation will be required for FDA to continue collectin",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-24",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/24/2025-20667/determination-of-regulatory-review-period-for-purposes-of-patent-extension-envision-mammography",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENVISION MAMMOGRAPHY PLATFORM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-24",
    "title": "Intercept Pharmaceuticals, Inc., et al.; Withdrawal of Approval of New Drug Application for OCALIVA (Obeticholic Acid) Tablets, 5 Milligrams and 10 Milligrams, and Three Abbreviated New Drug Applications for Obeticholic Acid Tablets, 5 Milligrams and 10 Milligrams",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/24/2025-20767/intercept-pharmaceuticals-inc-et-al-withdrawal-of-approval-of-new-drug-application-for-ocaliva",
    "abstract": "The Food and Drug Administration (FDA) is withdrawing approval of the new drug application (NDA) for OCALIVA (obeticholic acid) tablets, 5 milligrams (mg) and 10 mg, held by Intercept Pharmaceuticals, Inc., 305 Madison Ave., Morristown, NJ 07960 (Intercept). In addition, FDA is withdrawing approval of three abbreviated new drug applications (ANDAs) for obeticholic acid tablets, 5 mg and 10 mg, from three separate ANDA holders. Intercept voluntarily requested withdrawal of its NDA, and Apotex, In",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-21",
    "title": "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Small Dispensers Assessment Under the Drug Supply Chain Security Act",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/21/2025-20643/agency-information-collection-activities-submission-for-office-of-management-and-budget-review",
    "abstract": "The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-21",
    "title": "Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/21/2025-20548/product-specific-guidances-draft-and-revised-draft-guidances-for-industry-availability",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product- specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled \"Bioequivalence Recommendations for Specific Products\" tha",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-20",
    "title": "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/20/2025-20380/scientific-considerations-in-demonstrating-biosimilarity-to-a-reference-product-updated",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies.\" This draft guidance describes considerations regarding a comparative clinical study or studies with efficacy endpoints (a comparative efficacy study or CES) intended to support a demonstration that a proposed ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-18",
    "title": "Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments; Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/18/2025-20153/patient-focused-drug-development-selecting-developing-or-modifying-fit-for-purpose-clinical-outcome",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry, FDA staff, and other stakeholders entitled \"Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments.\" This guidance (Guidance 3) is the third in a series of four methodological patient-focused drug development (PFDD) guidance documents that describe how stakeholders (patients, researchers, medical product developers, and othe",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-17",
    "title": "Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers; Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/17/2025-19984/expanded-access-to-investigational-drugs-for-treatment-use-questions-and-answers-guidance-for",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers.\" This guidance finalizes the revised draft guidance issued on November 2, 2022, and replaces the final guidance of the same title issued in June 2016 and updated in October 2017. The guidance addresses frequently asked questions, including those related to the implementation of FDA's regulatio",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-17",
    "title": "Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use; Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/17/2025-19990/considerations-for-waiver-requests-for-ph-adjusters-in-generic-drug-products-intended-for-parenteral",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use.\" This guidance is intended to assist abbreviated new drug application (ANDA) applicants that reference a drug product intended for parenteral, ophthalmic, or otic use in seeking approval of a drug that is qualitatively (Q1) different or quantitativel",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-17",
    "title": "Menstrual Products-Performance Testing and Labeling Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/17/2025-19948/menstrual-products-performance-testing-and-labeling-recommendations-draft-guidance-for-industry-and",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Menstrual Products-- Performance Testing and Labeling Recommendations.\" This draft guidance document provides recommendations for performance testing, labeling, and information for inclusion in premarket notification (510(k)) submissions, when necessary, for certain menstrual products. The recommendations in this guidance apply to tampons, pads, and menstrual cups used to absorb or col",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-11-17",
    "title": "Quality Management System Information for Certain Premarket Submission Reviews; Draft Guidance for Industry and Food and Drug Administration Staff; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/11/17/2025-19947/quality-management-system-information-for-certain-premarket-submission-reviews-draft-guidance-for",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled \"Quality Management System Information for Certain Premarket Submission Reviews.\" The medical device current good manufacturing practice (CGMP) requirements, previously in the quality system regulation (QS regulation) and now the quality management system regulation (QMSR), have been amended effective February 2, 2026, to align more closely with the international consensus standard for ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-10-16",
    "title": "Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs With a New World Screwworm-Related Indication; Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/10/16/2025-19565/dual-labeling-for-fully-approved-and-conditionally-approved-new-animal-drugs-with-a-new-world",
    "abstract": "The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for industry (GFI) #299 entitled \"Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs With a New World Screwworm-Related Indication.\" This guidance is intended to inform new animal drug sponsors that dual labeling of a new animal drug product may include an intended use that is fully approved under section 512(b) of the Federal Food, Drug, and Cosmetic Act (FD&C A",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-10-02",
    "title": "Revocation of Emergency Use of a Biological Product; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/10/02/2025-19270/revocation-of-emergency-use-of-a-biological-product-availability",
    "abstract": "The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (ASPR/HHS) for COVID-19 convalescent plasma. FDA revoked the Authorization under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocation, which includes an explanation of the reasons for the revocation, is reprinted in this document.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-10-02",
    "title": "Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/10/02/2025-19345/product-specific-guidances-draft-and-revised-draft-guidances-for-industry-availability",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product- specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled \"Bioequivalence Recommendations for Specific Products\" tha",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-10-02",
    "title": "Revocation of Emergency Use of Three Biological Products; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/10/02/2025-19272/revocation-of-emergency-use-of-three-biological-products-availability",
    "abstract": "The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUA) (the Authorizations) issued to Pfizer, Inc. for Pfizer-BioNTech COVID-19 Vaccine; to ModernaTX, Inc. for Moderna COVID-19 Vaccine; and to Novavax, Inc. for Novavax COVID-19 Vaccine, Adjuvanted. FDA revoked these Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocations, which include an explanation of the reasons for each revocation, are reprinted in this ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-10-01",
    "title": "Jason Oppenheimer: Final Debarment Order",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/10/01/2025-19162/jason-oppenheimer-final-debarment-order",
    "abstract": "The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Jason Oppenheimer for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Oppenheimer was convicted of one felony count under Federal law for the offense of possession with intent to distribute Tapentadol. The factual basis supporting Mr. Oppenheimer's conviction, as described below, is con",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-10-01",
    "title": "Yong Sheng Jiao: Denial of Application for Termination of Debarment",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/10/01/2025-19163/yong-sheng-jiao-denial-of-application-for-termination-of-debarment",
    "abstract": "The Food and Drug Administration (FDA) is denying Yong Sheng Jiao's application for termination of debarment under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Mr. Jiao was given notice of the proposed denial of his application for termination of his debarment and was given an opportunity to request a hearing to show why his application for termination of debarment should be granted. As of June 16, 2025 (30 days after receipt of the notice), Mr. Jiao had not requested a hearing and throu",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-30",
    "title": "E20 Adaptive Designs for Clinical Trials; International Council for Harmonisation; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/30/2025-18897/e20-adaptive-designs-for-clinical-trials-international-council-for-harmonisation-draft-guidance-for",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"E20 Adaptive Designs for Clinical Trials.\" The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is intended to provide a transparent and harmonized set of recommendations for clinical trials with an adaptive design. The draft guidance focuses on ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-29",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; MIPLYFFA",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/29/2025-18786/determination-of-regulatory-review-period-for-purposes-of-patent-extension-miplyffa",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MIPLYFFA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-29",
    "title": "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Mitigation Strategies To Protect Food Against Intentional Adulteration",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/29/2025-18811/agency-information-collection-activities-submission-for-office-of-management-and-budget-review",
    "abstract": "The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-29",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; DIAMONDBACK 360 CORONARY ORBITAL ATHERECTOMY DEVICE",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/29/2025-18780/determination-of-regulatory-review-period-for-purposes-of-patent-extension-diamondback-360-coronary",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DIAMONDBACK 360 CORONARY ORBITAL ATHERECTOMY DEVICE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-29",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; TRICLIP",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/29/2025-18781/determination-of-regulatory-review-period-for-purposes-of-patent-extension-triclip",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TRICLIP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-29",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; NIKTIMVO",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/29/2025-18809/determination-of-regulatory-review-period-for-purposes-of-patent-extension-niktimvo",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NIKTIMVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-25",
    "title": "Prior Notice: Adding Requirement To Submit Mail Tracking Number for Articles of Food Arriving by International Mail and Timeframe for Post-Refusal and Post-Hold Submissions",
    "type": "Rule",
    "link": "https://www.federalregister.gov/documents/2025/09/25/2025-18655/prior-notice-adding-requirement-to-submit-mail-tracking-number-for-articles-of-food-arriving-by",
    "abstract": "The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to amend its prior notice regulation to add a requirement that prior notice and food facility registration information be submitted within a certain timeframe after certain notices of refusal or hold have been issued (\"post-refusal\" and \"post-hold\" submission) or responses to requests for FDA review have been issued and beginning October 1, 2026, add a requirement that the prior notice for articles of food arriving",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-25",
    "title": "Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/25/2025-18651/innovative-designs-for-clinical-trials-of-cellular-and-gene-therapy-products-in-small-populations",
    "abstract": "The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a draft document entitled \"Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations.\" The draft guidance document provides recommendations to sponsors who are planning clinical trials of cell and gene therapy (CGT) products intended for use in a disease or condition that affects a small population, generally one that meets the definition of a rare disease or condit",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-25",
    "title": "Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/25/2025-18653/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-draft-guidance-for",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft document entitled \"Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry.\" The draft guidance document provides sponsors engaged in the development of regenerative medicine therapies for serious or life-threatening diseases or conditions with FDA's recommendations on the expedited development and review of these therapies. This draft guidance, when ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-25",
    "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practices for Positron Emission Tomography Drugs",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/25/2025-18620/agency-information-collection-activities-proposed-collection-comment-request-current-good",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits c",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-25",
    "title": "Postapproval Methods To Capture Safety and Efficacy Data for Cell and Gene Therapy Products; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/25/2025-18650/postapproval-methods-to-capture-safety-and-efficacy-data-for-cell-and-gene-therapy-products-draft",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft document entitled \"Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products; Draft Guidance for Industry.\" The draft guidance document discusses methods and approaches for capturing postapproval safety and efficacy data for cell and gene therapy (CGT) products. Given the potential for long-lasting effects of CGT products, and the generally limited number of participa",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-24",
    "title": "Computer Software Assurance for Production and Quality System Software; Guidance for Industry and Food and Drug Administration Staff; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/24/2025-18468/computer-software-assurance-for-production-and-quality-system-software-guidance-for-industry-and",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Computer Software Assurance for Production and Quality System Software.\" FDA is issuing this guidance to provide recommendations on computer software assurance for computers and automated data processing systems used as part of medical device production or the quality system. FDA believes that these recommendations will help foster the adoption and use of innovative technologies that pro",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-24",
    "title": "ADUFA V Third-Party Assessment Report: Notice of Availability; Virtual Public Meeting; Request for Comments",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/24/2025-18483/adufa-v-third-party-assessment-report-notice-of-availability-virtual-public-meeting-request-for",
    "abstract": "The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a report entitled \"ADUFA V Third-Party Assessment Report\" and a related virtual public meeting. The purpose of the virtual public meeting is to provide an overview of a third- party assessment that examines the implementation of the Animal Drug User Fee Act (ADUFA). FDA is soliciting comments on the assessment.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-23",
    "title": "Consideration of Enforcement Policies for In Vitro Diagnostic Tests During a Section 564 Declared Emergency; Guidance for Industry and Food and Drug Administration Staff; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/23/2025-18402/consideration-of-enforcement-policies-for-in-vitro-diagnostic-tests-during-a-section-564-declared",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Consideration of Enforcement Policies for In Vitro Diagnostic Tests During a Section 564 Declared Emergency.\" This guidance describes the factors FDA intends to assess in deciding whether to issue an enforcement policy regarding in vitro diagnostic test manufacturers' offering of certain unapproved in vitro diagnostic tests and unapproved uses of approved in vitro diagnostic tests during",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-23",
    "title": "Malaria: Developing Drugs for Treatment; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/23/2025-18407/malaria-developing-drugs-for-treatment-draft-guidance-for-industry-availability",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Malaria: Developing Drugs for Treatment.\" The purpose of this draft guidance is to assist sponsors in the overall development program for drug and biological products for the treatment of malaria, caused by clinically relevant Plasmodium species.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-22",
    "title": "Advancing the Development of Pediatric Therapeutics (ADEPT) 10: Addressing Challenges in Neonatal Product Development-Leveraging Rare Disease Frameworks; Public Meeting",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/22/2025-18273/advancing-the-development-of-pediatric-therapeutics-adept-10-addressing-challenges-in-neonatal",
    "abstract": "The Food and Drug Administration (FDA or we) is announcing the following public workshop entitled \"Advancing the Development of Pediatric Therapeutics (ADEPT) 10: Addressing Challenges in Neonatal Product Development--Leveraging Rare Disease Frameworks.\" The aim of the public workshop is to discuss common challenges in neonatal and rare disease product development and identify opportunities to leverage rare disease product development frameworks in the neonatal product development space.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-19",
    "title": "Safety Labeling Changes-Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/19/2025-18152/safety-labeling-changes-implementation-of-section-505o4-of-the-federal-food-drug-and-cosmetic-act",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Safety Labeling Changes--Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act.\" This draft guidance provides information on the implementation of the statutory provision that authorizes FDA to require application holders for certain drug and biological products to make labeling changes based on new safety information that becomes available after ap",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-19",
    "title": "William Goldsmith: Final Debarment Order",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/19/2025-18213/william-goldsmith-final-debarment-order",
    "abstract": "The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) debarring William Goldsmith for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Goldsmith was convicted of one felony count under Federal law for introducing misbranded drugs into interstate commerce. The factual basis supporting Mr. Goldsmith's conviction, as described below, is conduct rela",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-19",
    "title": "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Environmental Impact Considerations",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/19/2025-18188/agency-information-collection-activities-submission-for-office-of-management-and-budget-review",
    "abstract": "The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.",
    "matching_keywords": [
      "mental"
    ]
  },
  {
    "date": "2025-09-18",
    "title": "Radiological Health Regulations; Technical Amendments",
    "type": "Rule",
    "link": "https://www.federalregister.gov/documents/2025/09/18/2025-18080/radiological-health-regulations-technical-amendments",
    "abstract": "The Food and Drug Administration (FDA) is making technical amendments to its radiological health regulations to correct an error. On January 20, 2023, FDA published a final rule entitled \"Radiological Health Regulations; Amendments to Records and Reports for Radiation Emitting Electronic Products; Amendments to Performance Standards for Diagnostic X-ray, Laser, and Ultrasonic Products\" that inadvertently deleted certain existing regulatory text from the Code of Federal Regulations. This action c",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-18",
    "title": "Fee Rate for Using a Priority Review Voucher in Fiscal Year 2026",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/18/2025-18075/fee-rate-for-using-a-priority-review-voucher-in-fiscal-year-2026",
    "abstract": "The Food and Drug Administration (FDA or the Agency) is announcing the fee rate for using a priority review voucher for fiscal year (FY) 2026. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended, authorizes FDA to determine and collect priority review user fees for certain applications for review of human drug or biological products when those applications use a tropical disease, rare pediatric disease, or material threat medical countermeasure (MCM) priority review voucher. These vo",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-17",
    "title": "Erosive Esophagitis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/17/2025-18001/erosive-esophagitis-developing-drugs-for-treatment-draft-guidance-for-industry-availability",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Erosive Esophagitis: Developing Drugs for Treatment.\" The draft guidance details recommendations on clinical trials for drugs being developed for the healing of erosive esophagitis (EE) and maintenance of healed EE in adults, including considerations for eligibility criteria, trial design features, efficacy evaluations, and safety assessments.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-17",
    "title": "Disseminated Coccidioidomycosis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/17/2025-18002/disseminated-coccidioidomycosis-developing-drugs-for-treatment-draft-guidance-for-industry",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Disseminated Coccidioidomycosis: Developing Drugs for Treatment.\" The purpose of this draft guidance is to assist sponsors in the clinical development of drugs for the treatment of disseminated coccidioidomycosis caused by Coccidioides species (i.e., C. immitis and C. posadasii).",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-17",
    "title": "Symptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for Treatment; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/17/2025-18000/symptomatic-nonerosive-gastroesophageal-reflux-disease-developing-drugs-for-treatment-draft-guidance",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Symptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for Treatment.\" The draft guidance details FDA's recommendations on the clinical trials for drugs being developed for the treatment of symptomatic nonerosive gastroesophageal reflux disease (sGERD) in adults, including considerations for eligibility criteria, trial design features, efficacy evaluat",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-12",
    "title": "Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications; Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/12/2025-17698/alternative-tools-assessing-drug-manufacturing-facilities-identified-in-pending-applications",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications.\" This guidance provides information to applicants on how FDA intends to use alternative tools to assess drug manufacturing facilities identified in a marketing application (i.e., a new drug application (NDA), an abbreviated new drug application (ANDA), a biologics license applicati",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-12",
    "title": "Digital Health Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Generative Artificial Intelligence-Enabled Digital Mental Health Medical Devices",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/12/2025-17651/digital-health-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request-for",
    "abstract": "The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Digital Health Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA. The meeting will be open to the public. FDA is establishing a docket for public comment.",
    "matching_keywords": [
      "mental health",
      "artificial intelligence",
      "mental"
    ]
  },
  {
    "date": "2025-09-11",
    "title": "Development of Non-Opioid Analgesics for Chronic Pain, Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/11/2025-17442/development-of-non-opioid-analgesics-for-chronic-pain-draft-guidance-for-industry-availability",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Development of Non-Opioid Analgesics for Chronic Pain.\" This guidance is intended to assist sponsors in the development of non- opioid analgesics for the treatment of chronic pain. It describes FDA's current recommendations regarding phase 3 trials for prescription non- opioid analgesic products being developed to treat chronic pain. This guidance also responds to the statut",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-09",
    "title": "Classification Categories for Certain Supplements Under Biosimilar User Fee Amendments III; Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/09/2025-17290/classification-categories-for-certain-supplements-under-biosimilar-user-fee-amendments-iii-guidance",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Classification Categories for Certain Supplements Under BsUFA III.\" This guidance provides recommendations for applicants on classification categories A, B, C, D, E, and F for original and resubmitted prior approval supplements submitted to approved applications for biosimilar and interchangeable biosimilar products under the Public Health Service Act (PHS Act). The commitme",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-09",
    "title": "E6(R3) Good Clinical Practice; International Council for Harmonisation; Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/09/2025-17311/e6r3-good-clinical-practice-international-council-for-harmonisation-guidance-for-industry",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"E6(R3) Good Clinical Practice.\" The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance includes a principles document and annex 1 and is the precursory guidance to the draft guidance entitled \"E6(R3) Good Clinical Practice: Annex 2.\" Once complete, the guidanc",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-09",
    "title": "M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry; Reopening of the Comment Period",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/09/2025-17292/m13b-bioequivalence-for-immediate-release-solid-oral-dosage-forms-additional-strengths-biowaiver",
    "abstract": "The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the draft guidance announced in the notice entitled \"M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry,\" published in the Federal Register of June 2, 2025. The Agency is taking this action to allow interested persons additional time to submit comments.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-09",
    "title": "Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations; Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/09/09/2025-17226/development-of-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations.\" This guidance describes the Agency's recommendations on the design and evaluation of comparative analytical studies intended to support a demonstration that a proposed therapeutic protein product is biosimilar to a reference product licensed under the ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-09-04",
    "title": "Food Additives Permitted for Direct Addition to Food for Human Consumption; Vitamin D3 in Yogurt and Other Cultured Dairy Products Fermented With Lactobacillus delbrueckii, Subspecies bulgaricus, and Streptococcus thermophilus",
    "type": "Rule",
    "link": "https://www.federalregister.gov/documents/2025/09/04/2025-16946/food-additives-permitted-for-direct-addition-to-food-for-human-consumption-vitamin-d3-in-yogurt-and",
    "abstract": "The Food and Drug Administration (FDA or we) is amending the food additive regulations to provide for the safe use of vitamin D<INF>3</INF> as a nutrient supplement in yogurt and other cultured dairy products fermented with Lactobacillus delbrueckii, subspecies bulgaricus (L. delbrueckii, subsp. bulgaricus), and Streptococcus thermophilus (S. thermophilus) at a level higher than is currently permitted. We are taking this action in response to a food additive petition filed by General Mills, Inc.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-29",
    "title": "Amylyx Pharmaceuticals, Inc.; Withdrawal of Approval of New Drug Application for RELYVRIO (Sodium Phenylbutyrate and Taurursodiol) for Suspension, 3 Gram/Packet and 1 Gram/Packet",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/29/2025-16646/amylyx-pharmaceuticals-inc-withdrawal-of-approval-of-new-drug-application-for-relyvrio-sodium",
    "abstract": "The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) for RELYVRIO (sodium phenylbutyrate and taurursodiol) for suspension, 3 gram (g)/ packet and 1 g/packet, held by Amylyx Pharmaceuticals, Inc. (Amylyx), 43 Thorndike St., Cambridge, MA 02141. Amylyx has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-28",
    "title": "Issuance of Priority Review Voucher; Rare Pediatric Disease Product; MODESYO (dordaviprone)",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/28/2025-16515/issuance-of-priority-review-voucher-rare-pediatric-disease-product-modesyo-dordaviprone",
    "abstract": "The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that MODESYO (dordaviprone), approved August 6",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-26",
    "title": "Determination That Four Heparin Sodium In Sodium Chloride In Plastic Container (Heparin Sodium) Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/26/2025-16349/determination-that-four-heparin-sodium-in-sodium-chloride-in-plastic-container-heparin-sodium-drug",
    "abstract": "The Food and Drug Administration (FDA or Agency) has determined that HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (heparin sodium) injectable, 5,000 units/100 milliliters (mL); HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (heparin sodium) injectable, 5,000 units/100 mL; HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (heparin sodium) injectable, 10,000 units/100 mL; and HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLOR",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-26",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; LUMISIGHT",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/26/2025-16266/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumisight",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUMISIGHT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-26",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; OHTUVAYRE",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/26/2025-16272/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ohtuvayre",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OHTUVAYRE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-26",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; PIASKY",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/26/2025-16274/determination-of-regulatory-review-period-for-purposes-of-patent-extension-piasky",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PIASKY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-26",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; VORANIGO",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/26/2025-16271/determination-of-regulatory-review-period-for-purposes-of-patent-extension-voranigo",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VORANIGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-26",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; IQIRVO",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/26/2025-16265/determination-of-regulatory-review-period-for-purposes-of-patent-extension-iqirvo",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IQIRVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-26",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; SOFDRA",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/26/2025-16275/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sofdra",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOFDRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claim that human drug product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-26",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; ZUNVEYL",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/26/2025-16270/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zunveyl",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZUNVEYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-26",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/26/2025-16269/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yorvipath",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YORVIPATH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claim that human drug product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-26",
    "title": "Determination of Regulatory Review Period for Purposes of Patent Extension; NEMLUVIO",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/26/2025-16267/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nemluvio",
    "abstract": "The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NEMLUVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-22",
    "title": "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishing and Maintaining Lists of United States Establishments With Interest in Exporting Human Food Program-Regulated Products",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/22/2025-16075/agency-information-collection-activities-submission-for-office-of-management-and-budget-review",
    "abstract": "The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-22",
    "title": "Animal Studies for Dental Bone Grafting Material Devices-Premarket Notification (510(k)) Submissions; Guidance for Industry and Food and Drug Administration Staff; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/22/2025-16137/animal-studies-for-dental-bone-grafting-material-devices-premarket-notification-510k-submissions",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Animal Studies for Dental Bone Grafting Material Devices--Premarket Notification (510(k)) Submissions.\" This guidance document provides recommendations for animal study design and animal study information to include to support a 510(k) submission for dental bone grafting material devices. This guidance may help manufacturers comply with some special controls for dental bone grafting mate",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-22",
    "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Animal Food and Egg Regulatory Program Standards",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/22/2025-16064/agency-information-collection-activities-proposed-collection-comment-request-animal-food-and-egg",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits c",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-22",
    "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Tobacco Retailer Training Programs",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/22/2025-16068/agency-information-collection-activities-proposed-collection-comment-request-tobacco-retailer",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits c",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-22",
    "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/22/2025-16067/agency-information-collection-activities-proposed-collection-comment-request-regulations-restricting",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits c",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-22",
    "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational Device Exemptions Reports and Records",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/22/2025-16066/agency-information-collection-activities-proposed-collection-comment-request-investigational-device",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits c",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-21",
    "title": "Listing of Color Additives Exempt From Certification; Galdieria Extract Blue; Confirmation of Effective Date",
    "type": "Rule",
    "link": "https://www.federalregister.gov/documents/2025/08/21/2025-16046/listing-of-color-additives-exempt-from-certification-galdieria-extract-blue-confirmation-of",
    "abstract": "The Food and Drug Administration (FDA or we) is confirming the effective date of June 26, 2025, for the final order that appeared in the Federal Register of May 12, 2025. The final order amends the color additive regulations to provide for the safe use of galdieria extract blue as a color additive at levels consistent with good manufacturing practice (GMP) in: non-alcoholic beverages and beverage bases, fruit drinks, fruit smoothies, fruit juices, vegetable juices, dairy-based smoothies, milk sh",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-21",
    "title": "Listing of Color Additives Exempt From Certification; Butterfly Pea Flower Extract; Confirmation of Effective Date",
    "type": "Rule",
    "link": "https://www.federalregister.gov/documents/2025/08/21/2025-16045/listing-of-color-additives-exempt-from-certification-butterfly-pea-flower-extract-confirmation-of",
    "abstract": "The Food and Drug Administration (FDA or we) is confirming the effective date of June 26, 2025, for the final order that appeared in the Federal Register of May 12, 2025. The final order amends the color additive regulations to provide for the expanded safe use of butterfly pea flower extract as a color additive at levels consistent with good manufacturing practice (GMP) in: ready-to-eat cereals, crackers, snack mixes, hard pretzels, plain potato chips (restructured or baked), and plain corn chi",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-19",
    "title": "Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/19/2025-15797/oncology-therapeutic-radiopharmaceuticals-dosage-optimization-during-clinical-development-draft",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development.\" This guidance is intended to assist sponsors in identifying an optimized dosage for radiopharmaceutical therapies (RPT) for oncology indications during clinical development and prior to submitting a marketing application for a new indication and usage. The guidance provides cons",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-19",
    "title": "Doyal Kalita: Final Debarment Order",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/19/2025-15787/doyal-kalita-final-debarment-order",
    "abstract": "The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Doyal Kalita for a period of 10 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Kalita was convicted of two felony counts under Federal law. The factual basis supporting Mr. Kalita's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-19",
    "title": "Approaches to Assessment of Overall Survival in Oncology Clinical Trials; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/19/2025-15796/approaches-to-assessment-of-overall-survival-in-oncology-clinical-trials-draft-guidance-for-industry",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Approaches to Assessment of Overall Survival in Oncology Clinical Trials.\" The purpose of this draft guidance is to provide recommendations to sponsors on the assessment of overall survival in randomized oncology clinical trials conducted to support marketing approval of drugs and biological products, with an emphasis on the analysis of overall survival as a prespecified saf",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-15",
    "title": "Revocation of Authorization of Emergency Use of In Vitro Diagnostic Device for Detection and/or Diagnosis of COVID-19; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/15/2025-15556/revocation-of-authorization-of-emergency-use-of-in-vitro-diagnostic-device-for-detection-andor",
    "abstract": "The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to LumiraDx UK Ltd. for the LumiraDx SARS CoV-2 RNA STAR Complete. FDA revoked the Authorization under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocation, which includes an explanation of the reason for revocation, is reprinted at the end of this document.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-15",
    "title": "Biosimilar User Fee Act III Regulatory Science Program Interim Public Meeting; Public Meeting; Interim Report; Availability; Request for Comments",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/15/2025-15571/biosimilar-user-fee-act-iii-regulatory-science-program-interim-public-meeting-public-meeting-interim",
    "abstract": "The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled \"Biosimilar User Fee Act (BsUFA) III Regulatory Science Program Interim Public Meeting\" and the availability of the report entitled \"BsUFA III Regulatory Science Pilot Program Interim Report.\" The purpose of the public meeting is to review the progress of the BsUFA III Regulatory Science Program aims, or demonstration projects, and to solicit input on future research priorities. Under th",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-08",
    "title": "Product-Specific Guidance on Iron Sucrose; Draft Guidance for Industry; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/08/2025-15082/product-specific-guidance-on-iron-sucrose-draft-guidance-for-industry-availability",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a revised draft guidance for industry entitled \"Draft Guidance on Iron Sucrose.\" This revised draft guidance, when finalized, will provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for iron sucrose intravenous injectable.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-07",
    "title": "Requirements for Additional Traceability Records for Certain Foods: Compliance Date Extension",
    "type": "Proposed Rule",
    "link": "https://www.federalregister.gov/documents/2025/08/07/2025-14967/requirements-for-additional-traceability-records-for-certain-foods-compliance-date-extension",
    "abstract": "The Food and Drug Administration is proposing to extend the compliance date for the final rule, \"Requirements for Additional Traceability Records for Certain Foods,\" due to concerns about the amount of time affected entities will need to implement the requirements of the rule. If finalized, this rule would extend the compliance date by 30 months from January 20, 2026, to July 20, 2028.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-07",
    "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Humanitarian Use Devices",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/07/2025-14945/agency-information-collection-activities-proposed-collection-comment-request-medical-devices",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits c",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-07",
    "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Collection of Conflict-of-Interest Information for Participation in Food and Drug Administration Non-Employee Fellowship and Traineeship Programs",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/07/2025-14948/agency-information-collection-activities-proposed-collection-comment-request-collection-of",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits c",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-07",
    "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Testing Communications on Medical Devices and Radiation-Emitting Products",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/07/2025-14946/agency-information-collection-activities-proposed-collection-comment-request-testing-communications",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits c",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-06",
    "title": "Food Standards of Identity Modernization; Pasteurized Orange Juice",
    "type": "Proposed Rule",
    "link": "https://www.federalregister.gov/documents/2025/08/06/2025-14949/food-standards-of-identity-modernization-pasteurized-orange-juice",
    "abstract": "The Food and Drug Administration (FDA or we) is proposing to amend the standard of identity for pasteurized orange juice (POJ) by lowering the minimum orange juice soluble solids content from 10.5[deg] to 10[deg] Brix. We tentatively conclude that this proposed amendment will promote honesty and fair dealing in the interest of consumers and provide industry greater flexibility in the manufacture of pasteurized orange juice. This action, if finalized, will respond to a citizen petition submitted ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-04",
    "title": "Determination That HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (Heparin Sodium) Injectable, 200 Units/100 Milliliters, and Two Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/04/2025-14690/determination-that-heparin-sodium-1000-units-in-sodium-chloride-09-in-plastic-container-heparin",
    "abstract": "The Food and Drug Administration (FDA or Agency) has determined that HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (heparin sodium) injectable, 200 units/100 milliliters (mL); HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (heparin sodium) injectable, 200 units/100 mL; and HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (heparin sodium) injectable, 1,000 units/100 mL under new drug application (NDA) 019042 were not withdr",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-08-04",
    "title": "Prescription Drug User Fee Act VII; Independent Assessment of Communication Through Product Quality Information Requests During Application Review; Final Report; Availability; Reopening of Comment Period",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/08/04/2025-14684/prescription-drug-user-fee-act-vii-independent-assessment-of-communication-through-product-quality",
    "abstract": "The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the notice of availability entitled \"Prescription Drug User Fee Act VII; Independent Assessment of Communication Through Product Quality Information Requests During Application Review; Final Report; Availability; Request for Comments\" that appeared in the Federal Register of May 9, 2025. In the notice of availability, FDA requested comments on the final assessment report. The Agency is taking this action in ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-07-31",
    "title": "Medical Device User Fee Small Business Qualification and Determination Guidance Final Guidance for Industry and Food and Drug Administration Staff and Foreign Governments; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/07/31/2025-14460/medical-device-user-fee-small-business-qualification-and-determination-guidance-final-guidance-for",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Medical Device User Fee Small Business Qualification and Determination Guidance.\" This guidance updates the previous version of the guidance, titled \"Medical Device User Fee Small Business Qualification and Certification Guidance\", issued on August 1, 2018. The guidance includes updates which describe how FDA plans to determine if a small business is experiencing \"financial ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-07-30",
    "title": "Biosimilar User Fee Rates for Fiscal Year 2026",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/07/30/2025-14416/biosimilar-user-fee-rates-for-fiscal-year-2026",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the rates for biosimilar user fees for fiscal year (FY) 2026. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Biosimilar User Fee Amendments of 2022 (BsUFA III), authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development; review of certain applications for approval of biosimilar biological products; and each biosimilar biological produ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-07-30",
    "title": "Animal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2026",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/07/30/2025-14409/animal-generic-drug-user-fee-program-rates-and-payment-procedures-for-fiscal-year-2026",
    "abstract": "The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2026 generic new animal drug program user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Generic Drug User Fee Amendments of 2023 (AGDUFA IV), authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, for certain sponsors of such abbreviated ",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-07-30",
    "title": "Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2026",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/07/30/2025-14414/food-safety-modernization-act-domestic-and-foreign-facility-reinspection-recall-and-importer",
    "abstract": "The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2026 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-07-30",
    "title": "Arthritis Advisory Committee; Termination",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/07/30/2025-14345/arthritis-advisory-committee-termination",
    "abstract": "The Food and Drug Administration (FDA or the Agency) is announcing the termination of the Agency's Arthritis Advisory Committee (Committee) by the Commissioner of Food and Drugs (Commissioner). The Commissioner has determined that it is not necessary to continue to maintain this Committee.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-07-30",
    "title": "Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2026",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/07/30/2025-14407/food-safety-modernization-act-voluntary-qualified-importer-program-user-fee-rate-for-fiscal-year",
    "abstract": "The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2026 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2025, and will remain in effect through September 30, 2026.",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-07-30",
    "title": "Prescription Drug User Fee Rates for Fiscal Year 2026",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/07/30/2025-14413/prescription-drug-user-fee-rates-for-fiscal-year-2026",
    "abstract": "The Food and Drug Administration (FDA, Agency, or we) is announcing the rates for prescription drug user fees for fiscal year (FY) 2026. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Prescription Drug User Fee Amendments of 2022 (PDUFA VII), authorizes FDA to collect application fees for certain applications for the review of human drug and biological products and prescription drug program fees for certain approved products. This notice establishes the fee rates for FY 2",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-07-30",
    "title": "Animal Drug User Fee Rates and Payment Procedures for Fiscal Year 2026",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/07/30/2025-14417/animal-drug-user-fee-rates-and-payment-procedures-for-fiscal-year-2026",
    "abstract": "The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2026 animal drug user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Drug User Fee Amendments of 2023 (ADUFA V), authorizes FDA to collect user fees for certain animal drug applications and supplemental animal drug applications, for certain animal drug products, for certain establishments where such products are made, and for certa",
    "matching_keywords": [
      "AI",
      "mental"
    ]
  },
  {
    "date": "2025-07-30",
    "title": "Medical Device User Fee Rates for Fiscal Year 2026",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/07/30/2025-14412/medical-device-user-fee-rates-for-fiscal-year-2026",
    "abstract": "The Food and Drug Administration (FDA) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2026. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2026, which",
    "matching_keywords": [
      "AI"
    ]
  },
  {
    "date": "2025-07-29",
    "title": "Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability",
    "type": "Notice",
    "link": "https://www.federalregister.gov/documents/2025/07/29/2025-14233/revocation-of-emergency-use-of-a-drug-product-during-the-covid-19-pandemic-availability",
    "abstract": "The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Regeneron Pharmaceuticals, Inc. (Regeneron) for REGEN-COV (casirivimab and imdevimab administered together), to GlaxoSmithKline LLC (GSK) for sotrovimab, to Eli Lilly and Company (Lilly) for bebtelovimab, and to AstraZeneca Pharmaceuticals LP (AstraZeneca) for EVUSHELD (tixagevimab co-packaged with cilgavimab). FDA revoked these Authorizations on December ",
    "matching_keywords": [
      "AI"
    ]
  }
]